Lipocine Stock Jumps On Litigation Settlement With Clarus Therapeutics

Lipocine Inc (NASDAQ:LPCN) has entered into a settlement and license agreement with Clarus Therapeutics to resolve claims in the ongoing intellectual property litigation and interference proceeding.
Under the terms of the settlement, both the companies have agreed to dismiss the litigation presently pending in the District Court for the District of Delaware.
Additionally, both parties have agreed on the interference proceedings presently pending in the U.S. Patent and Trademark.
The terms of the settlement remain confidential.
Price Action: LPCN shares are up 6.98% at $1.38 during the premarket session on the last check Thursday.